Navigation Links
Ondine to Present at Canaccord Adams 28th Annual Global Growth Conference
Date:8/6/2008

VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that its Chief Technology Officer, Dr. Nicolas Loebel, is scheduled to present at the 28th Annual Canaccord Adams Global Growth Conference at the Intercontinental Hotel in Boston, on Tuesday August 12th, 2008 at 1:00 p.m. Eastern Time.

Interested parties may access the live webcast by visiting the Company's website at http://www.ondinebiopharma.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software downloads that may be required to join the webcast. An audio archive of the presentation will be available for approximately 60 days.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development facility in Bothell, Washington, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: http://www.ondinebiopharma.com

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.


'/>"/>
SOURCE Ondine Biopharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
2. Atrium Innovations to Present at Upcoming 28th Annual Canaccord Adams Global Growth Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
4. Bionovo to Present at BMO Capital Markets 2008 Focus on Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
8. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
9. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... will feature Federal Hybrids, Inc. in an upcoming episode, scheduled to broadcast fourth ... Farmer will explore Federal Hybrids, the independent, family-owned seed company. Educating audiences about ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... stock market news outlet had provided a research update on Aytu Bioscience and ... TRT product. , According to Soulstring, prescription rates for Natesto® have more than ...
(Date:8/16/2017)... King of Prussia, PA (PRWEB) , ... August 16, 2017 , ... ... leaders will be taking part in sessions at the ISPE Annual Meeting and ... the Marriott Marquis San Diego Marina. The event’s theme is “Driving innovation to advance ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... a different cell type. Many treatments for specific cancers, such as breast, prostate, ... targeted treatment is androgen deprivation therapy for advanced prostate cancer. , This ...
Breaking Biology Technology:
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/23/2017)... report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), Product ... by MarketsandMarkets, the market is expected to be worth USD 18.98 billion by ... Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):